Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Eli Lilly & Co. LLY, +1.52% gained 0.3% in premarket trading on Monday after the drugmaker said it had started a Phase 1 trial for its experimental COVID-19 antibody treatment.

Lilly initiates Phase 1 clinical trial for a COVID-19 antibody treatment

Eli Lilly said on Monday patients have been dosed to test its potential antibody treatment designed to fight COVID-19, caused by the new coronavirus.

Eli Lilly starts human study of a potential coronavirus treatment

INDIANAPOLIS, June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic...

Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

INDIANAPOLIS, June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first to emerge...

Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research...

Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of...

Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

INDIANAPOLIS, May 29, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with...

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.

FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid

Shares of Eli Lilly & Co. LLY, +3.39% gained 0.8% in premarket trading on Friday, the day after the Food and Drug Administration (FDA) approved Tauvid, a drug used to help diagnose tau neurofibrillary tangles in people suspected of having Alzheimer's disease.

Lilly gets FDA approval for Alzheimer's diagnostic agent

It's not a treatment for this memory-robbing dementia, but it could help Lilly and its peers find one.

Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent

Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.

3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020

When AbCellera won a $30 million contract with the Defense Advanced Research Projects Agency to develop therapeutic countermeasures against viral outbreaks two years ago, it’s safe to assume that no one thought the technology would be so vitally important so soon. The work AbCellera was doing was part of a high-priority initiative from DARPA’s Biological […]

Eli Lilly’s COVID-19 therapy development partner AbCellera raises $105 million

Everbridge

QuidelOrtho Corp

Sprouts Farmers Markets

These fast movers are currently witnessing a short-term pullback in price. So, this could be a solid entry point for garnering better returns.

Top 4 Momentum Anomaly Stocks to Enhance Portfolio Returns

RIDGEFIELD, Conn. and INDIANAPOLIS, May 26, 2020 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI (EMPAgliflozin for the prevention of...

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

Xilinx

Here are a pair of stocks that will benefit from market strength.

Stocks This Week: Buy Eli Lilly And Xilinx

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Why Is Lilly (LLY) Down 5.5% Since Last Earnings Report?

AbbVie

These two pharma companies have outpaced the market this year, but which one will perform better than the other moving forward?

Better Buy: AbbVie vs. Eli Lilly

Chubb

Church & Dwight

Colgate-Palmolive

Con Ed

General Mills

Johnson Controls

Coca-Cola

Procter & Gamble

PPG Industries

Stanley Black & Decker

Exxon Mobil

York Water

When it comes to investing in dividend stocks, it's patience that results in the real payday for shareholders.

13 Dividend Stocks That Have Paid Investors for 100+ Years

Is  (LLY) Outperforming Other Medical Stocks This Year?

Is Eli Lilly and (LLY) Outperforming Other Medical Stocks This Year?

Eli Lilly’s stock moved nearly 90% between 2016 and 2019 even though the company barely had any revenue growth to show for it. So what got Eli Lilly’s investors excited?

How Eli Lilly’s Investors Cashed In 90% Capital Gains While Sales Barely Moved?

Visa

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

These stocks are doing better than the S&P 500 and pay a dividend.

3 Market-Beating Dividend Stocks to Buy Today

Tandem Diabetes Care

These two diabetes companies have been beating the market all year long, but that’s not the only reason you should consider investing in them.

2 Top Diabetes Stocks to Buy in May

Eli Lilly: Upward Growth Trend Can Continue

Anglogold Ashanti Plc

Clorox

Gold Fields Ltd.

It is an ideal time to invest in low-beta stocks since they might provide a shield against coronavirus-induced market volatility.

Fight Off the Coronavirus Blues With 5 Low-Beta Stocks

AstraZeneca

Bristol-Myers

Pfizer

Sanofi

Here we highlight five large drugmakers that can be added to one's portfolio amid the coronavirus crisis.

News for Eli Lilly Stock (LLY)